Statistics
The Cingulate stock price is currently $ 0.001600 with a total market cap valuation of $ 10,806 (6.75M shares outstanding). The Cingulate is trading on NASDAQ under the ticker sign CINGW. Cingulate price is up
Description
Cingulate Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to pioneering therapies for central nervous system and neurobiological conditions. Its leading investigational medicines are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed to manage attention deficit/hyperactivity disorders (ADHD). Furthermore, the company is progressing CTx-2103 for the treatment of anxiety disorders. Established in 2012, Cingulate Inc. maintains its main office in Kansas City, Kansas, and also operates a facility in Morristown, New Jersey.
Company Profile
- Full Name: Cingulate
- Sector: Healthcare
- Website: https://www.cingulate.com
